NCT07612020RecruitingPhase 1
A Phase 1, Randomized, Open-Label Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector (Part A) and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus IV (Part B) in Healthy Adult Participants
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- argenx
- Enrollment
- 130
- Locations
- 1
Study Overview
Brief Summary
This study aims to see how the body reacts to empasiprubart, administered using an autoinjector (AI). The study will also look at other effects of empasiprubart, how it works in the body, and if it is safe.
The study consists of 2 parts: parts A and B. In part A, eligible participants will be randomized to receive empasiprubart SC AI via abdomen, empasiprubart SC AI via thigh, or empasiprubart IV (intravenously). In part B, eligible participants will be randomized to receive empasiprubart SC AI via abdomen or empasiprubart IV.
Participants from part A will be in the study for approximately up to 37 weeks . Participants from part B will be in the study for up to approximately 43 weeks.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Is at least the local legal age of consent and aged 18 to 65 years, inclusive, when signing the ICF.
- •Has a body weight between 50 and 120 kg and a BMI between 18 and 35 kg/m2, inclusive.
Exclusion Criteria
- •Has any current or past clinically meaningful medical or psychiatric condition that, in the investigator's opinion, would confound the study results or put the participant at undue risk.
- •Clinical diagnosis of SLE. For participants with an antinuclear antibody titer of ≥1:80 and a positive anti-double-stranded DNA and/or positive anti-Smith result at screening, an SLE diagnosis must be ruled out before the first IMP administration.
- •Previously participated in an empasiprubart clinical study and received at least 1 dose of IMP.
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 3
A study to assess the efficacy and safety of empasiprubart in adults with CIDP2025-520805-10-00Argenx12
Active, not recruiting
Phase 1
A Study of Eltrekibart (LY3041658) in Healthy ParticipantsHealthyNCT07545590Eli Lilly and Company60
Active, not recruiting
Phase 3
A study to assess the efficacy and safety of Empasiprubart versus IVIg in adults with Multifocal Motor Neuropathy （empassion）一项在多灶性运动神经病成人患者中评价 Empasiprubart 对比 IVIg 的疗效和安全性的研究（empassion）多灶性运动神经病CTR20252964不适用 / 百时益医药研发（北京）有限公司
Recruiting
Phase 3
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisPrimary Sclerosing CholangitisNCT07387549Ipsen350
Recruiting
Not Applicable
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesSclerodermaNCT07470151Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12